69 related articles for article (PubMed ID: 8647573)
1. [HMG-CoA reductase inhibitors for prevention and treatment of coronary heart disease. Effective reduction of cardiac events and mortality].
Windler E
Fortschr Med; 1996 Mar; 114(8):89-90. PubMed ID: 8647573
[No Abstract] [Full Text] [Related]
2. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W; Forder P; Simes J; Hunt D; Tonkin A;
Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
[TBL] [Abstract][Full Text] [Related]
3. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.
Simes J; Furberg CD; Braunwald E; Davis BR; Ford I; Tonkin A; Shepherd J
Eur Heart J; 2002 Feb; 23(3):207-15. PubMed ID: 11792135
[TBL] [Abstract][Full Text] [Related]
4. Pravastatin and coronary heart disease.
Meyer FP
N Engl J Med; 1999 Apr; 340(14):1115-6; author reply 1116-7. PubMed ID: 10206830
[No Abstract] [Full Text] [Related]
5. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y
J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930
[TBL] [Abstract][Full Text] [Related]
6. Likely gains in life expectancy of patients with coronary artery disease treated with HMG-CoA reductase inhibitors, as predicted by a decision analysis model.
Kellett J
Eur J Surg; 1997 Jul; 163(7):539-46. PubMed ID: 9248989
[TBL] [Abstract][Full Text] [Related]
7. [Primary and secondary prevention of coronary disease by statins].
Ferrières J
Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):128-36. PubMed ID: 12555337
[TBL] [Abstract][Full Text] [Related]
8. [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
Sudhop T; von Bergmann K
MMW Fortschr Med; 2003 May; 145(21):19. PubMed ID: 12845862
[No Abstract] [Full Text] [Related]
9. [Statin treatment in type 2 diabetes. Is it a must today?].
Faust M
MMW Fortschr Med; 2003 Feb; 145(9):35-6. PubMed ID: 12666527
[No Abstract] [Full Text] [Related]
10. [Secondary prevention of coronary heart disease. How effective are modern therapy methods?].
Kolenda KD
Dtsch Med Wochenschr; 2003 Sep; 128(36):1849-53. PubMed ID: 12964107
[No Abstract] [Full Text] [Related]
11. [Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program].
Byington RP; Jukema JW; Salonen JT; Pitt B; Bruschke AV; Hoen H; Furberg CD; Mancini GB
Fortschr Med; 1996 Mar; 114(8):91-8. PubMed ID: 8647574
[TBL] [Abstract][Full Text] [Related]
12. Prevention of mortality from coronary heart disease with pravastatin.
Tonkin AM; Ryan EW
Biomed Pharmacother; 1999 Oct; 53(9):405-8. PubMed ID: 10554675
[TBL] [Abstract][Full Text] [Related]
13. Expected versus observed survival in 3 large population studies with HMG-CoA reductase inhibitors.
Naslafkih A; Sestier F
J Insur Med; 2000; 32(3):155-62. PubMed ID: 15912915
[TBL] [Abstract][Full Text] [Related]
14. [HMG-CoA reductase inhibitors in therapy of disorders of lipid metabolism].
Windler E; Greten H
Internist (Berl); 1993 Dec; 34(12):1107-14. PubMed ID: 8106206
[No Abstract] [Full Text] [Related]
15. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
[TBL] [Abstract][Full Text] [Related]
16. Predicting risk reduction of coronary disease in patients who are glucose intolerant: a comparison of treatment with fenofibrate and other lipid-modifying agents.
Haffner SM; Ashraf T
Manag Care Interface; 2000 Mar; 13(3):52-8. PubMed ID: 11066277
[TBL] [Abstract][Full Text] [Related]
17. [Atherosclerosis and simvastatin: new questions for the new millennium].
Tubaro M; Guido V; Sciarra L; Mustilli M; Carbone MA; D'Errico F
Ann Ital Med Int; 2000; 15(1):108-14. PubMed ID: 10842900
[TBL] [Abstract][Full Text] [Related]
18. [For coronary disease patients is certain: the lower the LDL the better].
MMW Fortschr Med; 2006 Jun; 148(24):6. PubMed ID: 16850797
[No Abstract] [Full Text] [Related]
19. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery.
Collard CD; Body SC; Shernan SK; Wang S; Mangano DT; ;
J Thorac Cardiovasc Surg; 2006 Aug; 132(2):392-400. PubMed ID: 16872968
[TBL] [Abstract][Full Text] [Related]
20. [Prevention and treatment of coronary heart disease: lowering LDL, increasing HDL or monitoring both?].
Windler E
Internist (Berl); 1996 Jun; 37(6):643-6. PubMed ID: 8768000
[No Abstract] [Full Text] [Related]
[Next] [New Search]
